Drug Trial Radar · NCT05907304
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
86
Actual
Start
Aug 17, 2023
Primary completion
Jul 1, 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- Erasca, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors
Conditions
- Advanced or Metastatic Solid Tumors
Interventions
NaporafenibDrug
Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor
TrametinibDrug
Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumorsTime frame: Assessed up to 24 months from time of first dose
Locations
29 sites in 5 countries. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Yale Cancer Center
New Haven, Connecticut
Florida Cancer Specialists - Sarasota
Sarasota, Florida
Florida Cancer Specialists - St. Petersburg
St. Petersburg, Florida
Emory University School of Medicine
Atlanta, Georgia
Henry Ford Health System
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
Comprehensive Cancer Center of Nevada (CCCN)
Las Vegas, Nevada
Oregon Health & Science University
Portland, Oregon
SCRI Oncology Partners (formerly Tennessee Oncology)
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Inova Schar Cancer Institute
Fairfax, Virginia
NEXT Virginia
Fairfax, Virginia
University of Wisconsin
Madison, Wisconsin
Linear Clinical Research, LTD
Perth, Australia
Macquarie University
Macquarie Park, New South Wales, Australia
St. Vincent's Hospital
Melbourne, Victoria, Australia
Cross Cancer Institute- Alberta Health Services (AHS)
Edmonton, Alberta, Canada
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
London Regional Cancer Center
London, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
National Cancer Center
Goyang-si, South Korea
Seoul National University Hospital Bundang
Gyeonggi-do, South Korea
Seoul National University Hospital
Seoul, South Korea
The Catholic University Hospital
Seoul, South Korea
Inje University Haeundae Paik Hospital
Busan, Busan Gwang'yeogsi, South Korea
Samsung Medical Center
Seoul, Seoul Teugbyeolsi, South Korea
Beatson West of Scotland Cancer Center
Glasgow, United Kingdom
Sarah Cannon Research Institute - HCA Healthcare
City of London, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.